Clinical Trials Browser

Interventional × Bone Marrow Diseases × Classical hematology × Clear all

NCT06303193 2026-06-05

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Recruiting

Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT07379125 2026-05-22

Therapeutic RSK1 Targeting in Myelofibrosis

Phase 1 Recruiting

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Splenomegaly, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT02452983 2022-06-02

SS1

Phase 1 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Preleukemia

NCT02055781 2021-11-18

PAC326

Phase 3 Terminated

311 enrolled 12 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Phase 3 Terminated

327 enrolled 11 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis